

PDA Task Force on Technical Report No. 29 (Revised 2012): Points to Consider for Cleaning Validation

Authors

Destin A. LeBlanc, Cleaning Validation Technologies
(Chair)

Gretchen Allison, Pfizer

Jennifer L. Carlson, Genentech

Koshy George, Consultant

Igor Gorsky, ConcordiaValSource

Irwin S. Hirsh, Novo Nordisk AS

Jamie Osborne, Siegfried (USA), Inc.

Greg Randall, Baxter Bioscience

Pierre-Michel Riss, Eli Lilly

George Verghese, STERIS Corporation

Jenn Walsh, Bristol-Myers Squibb

Vivienne Yankah, Sanofi-Pasteur, Ltd.

The content and views expressed in this Technical Report are the result of a consensus achieved by the authorizing Task Force and are not necessarily views of the organizations they represent.

Points to Consider for Cleaning Validation

Technical Report No. 29 (Revised 2012)

ISBN: 978-0-939459-48-3

© 2012 Parenteral Drug Association, Inc.

All rights reserved.



Paradigm Change in Manufacturing Operations (PCMOSM)

PDA launched the project activities related to the PCMO program in December 2008 to help implement the scientific application of the ICH Q8, Q9 and Q10 series. The PDA Board of Directors approved this program in cooperation with the Regulatory Affairs and Quality Advisory Board, and the Biotechnology Advisory Board and Science Advisory Board of PDA.

Although there are a number of acceptable pathways to address this concept, the PCMO program follows and covers the drug product lifecycle, employing the strategic theme of process robustness within the framework of the manufacturing operations. This project focuses on Pharmaceutical Quality Systems as an enabler of Quality Risk Management and Knowledge Management.


Using the Parenteral Drug Association's (PDA) membership expertise, the goal of the Paradigm Change in Manufacturing Operations Project is to drive the establishment of 'best practice' documents and /or training events in order to assist pharmaceutical manufacturers of Investigational Medicinal Products (IMPs) and commercial products in implementing the ICH guidelines on Pharmaceutical Development (ICH Q8, Q11), Quality Risk Management (ICH Q9) and Pharmaceutical Quality Systems (ICH Q10).

The PCMO program facilitates communication among the experts from industry, university and regulators as well as experts from the respective ICH Expert Working Groups and Implementation Working Group. PCMO task force members also contribute to PDA conferences and workshops on the subject.

PCMO follows the product lifecycle concept and has the following strategic intent:

- Enable an innovative environment for continual improvement of products and systems
- Integrate science and technology into manufacturing practice
- Enhance manufacturing process robustness, risk based decision making and knowledge management
- Foster communication among industry and regulatory authorities

The Product Life Cycle



For more information, including the PCMO Dossier, and to get involved, go to www.pda.org/pcmo

Table of Contents

1.0 Introduction.....	1	Cleaning Processes	20
1.1 Purpose/Scope	1	3.7 Standard Operating Procedures.....	21
2.0 Glossary of Terms	3	3.8 Operator Training for the Cleaning Process....	21
2.1 Definition of Acronyms	5	3.9 Introduction of New Products to a Validated Cleaning System	22
3.0 Cleaning Process Design and Development	7	4.0 Qualification	23
3.1 Cleaning Process Design	7	4.1 Protocol Elements.....	23
3.2 Cleaning Process Overview	8	4.2 Key Protocol Issues	23
3.2.1 Physical-chemical Aspects	9	4.2.1 Number of Runs in a Protocol.....	24
3.3 Design Considerations.....	10	4.2.2 Mock Soiling	24
3.3.1 Location of Cleaning	10	4.2.3 Worst-Case Process Conditions	24
3.3.1.1 In-Place Cleaning.....	10	4.2.4 Disposition of Products and Equipment during Validation.....	25
3.3.1.1.1 Clean-in-Place (CIP) Systems	10	4.3 Grouping/Family Approach	25
3.3.1.1.2 Solvent Reflux Cleaning	11	4.3.1 Product Grouping.....	26
3.3.1.1.3 Placebo Batches as a Cleaning Method	11	4.3.2 Equipment Grouping	26
3.3.1.2 Out-of-Place Cleaning.....	11	4.3.3 Introduction of a New Product or Equipment into a Group	27
3.3.1.2.1 Clean-Out-of-Place Systems.....	12	4.4 “Cleaning Verification” Documentation	27
3.3.2 Automated vs. Manual Systems	12	5.0 Residue and Limits	29
3.3.2.1 Manual Processes	12	5.1 Considerations for Developing Limits	29
3.3.2.2 Semi-Automated Processes	12	5.2 The Basis for Quantitative Limits.....	30
3.3.2.3 Automated Processes	13	5.3 Acceptable Concentration of Residue in Next Product	30
3.3.3 Soil Evaluation and Categorization.....	13	5.3.1 ARL Based on Drug Active Dose	30
3.3.3.1 Soil Categories	13	5.3.2 ARL Based on Toxicity.....	31
3.3.3.2 Soil Removal.....	13	5.3.2.1 ADE Determinations Based on ISPE’s Risk-MaPP.....	31
3.3.4 Equipment Considerations.....	14	5.3.2.2 Toxicity Calculations Based on LD ₅₀ Data	32
3.3.4.1 Dedicated – Nondedicated Manufacturing Equipment	14	5.3.3 Other ARL Determinations	33
3.3.4.2 Nonproduct Contact – Product Contact Surfaces.....	15	5.4 Acceptable Total Carryover	33
3.3.4.3 Low-Risk Sites – High-Risk Sites .	15	5.5 Surface Area Limit.....	34
3.3.4.4 Materials of Construction	15	5.6 Limit in Protocol Samples.....	34
3.3.5 Operational Considerations.....	15	5.6.1 Limit per Swab	34
3.3.6 Cleaning Agent Selection	16	5.6.2 Concentration Limit in Extracted Swab Solvent	34
3.3.7 Product Considerations.....	16	5.6.3 Concentration Limit in Rinse Sampling Solution.....	35
3.3.7.1 Product Risk Considerations.....	17	5.7 Consolidated Expressions.....	35
3.4 Cleaning Development		5.8 Example Calculations	36
Laboratory Experiments	17	5.9 Other Considerations	36
3.4.1 Soil Selection	17	5.9.1 Multiple Next Products.....	36
3.4.2 Parameter Selection	18	5.9.2 Next Product in Verification Approach.....	37
3.4.2.1 Parameter Interactions	19	5.9.3 Default Limits	37
3.4.3 Measurements to Determine Cleaning Effectiveness	19		
3.5 Cleaning Process Scale-Up.....	19		
3.5.1 Setting Process Controls	19		
3.6 Applying the “Design Space” Concept to			

FIGURES AND TABLES INDEX

Table 3.1-1	CPP and CQA Considerations that have Potential Risk Impact to a Cleaning Process 7	Table 6.1.2-2	Advantages and Limitations of Rinse Sampling..... 45
Table 3.1-2	The Cleaning Spectrum 8	Table 6.1.3-1	Advantages and Limitations of Swab/Wipe Sampling..... 47
Table 3.2-1	Cleaning Process Steps (Examples) 9	Figure 9.5-1	Documentation for Process Flow..... 74
Table 6.1.2-1	Comparison of Grab Sampling versus Separate Sampling Rinse..... 45		

